MMV adds two new key players to its worldwide R&D efforts
MMV and BioFocus DPI collaborate to identify antimalarial compounds
MMV will partner with BioFocus DPI, a UK-based leading provider of gene-to-drug candidate discovery services, to identify new natural product and small molecules that demonstrate antimalarial activity. The intention is to further optimize these hits as antimalarial therapeutics. Screening of BioFocus DPI’s compound collections has already generated many potential antimalarial product leads of high quality.
Chimerix joins international network of organizations to cure malaria
Chimerix, Inc., a biotechnology company based in Research Triangle Park, USA, developing orally available antiviral therapeutics, has joined the MMV and its network of partners to discover, develop and facilitate the delivery of new, effective and affordable antimalarial drugs. MMV will screen Chimerix’s chemical library to identify activity against malaria, and any lead candidates that result will be developed in partnership with South African-based iThemba Pharmaceuticals.
These are just two examples of some of the exciting new partnerships which MMV expects will result in important antimalarial product leads and eventual compounds that will not only treat the lethal falciparum malaria but also potentially tackle emerging resistance, stop malaria transmission, and target the rarer Plasmodium vivax malaria too.
View the press release for each partnership